Note: This document contains side effect information about vedolizumab. Some of the dosage forms listed on this page may not apply to the brand name Entyvio.
Common side effects of Entyvio include: nasopharyngitis. Other side effects include: upper respiratory tract infection and fatigue. See below for a comprehensive list of adverse effects.
Applies to vedolizumab: intravenous powder for solution
Along with its needed effects, vedolizumab (the active ingredient contained in Entyvio) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor or nurse immediately if any of the following side effects occur while taking vedolizumab:
Incidence not known
Some side effects of vedolizumab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Applies to vedolizumab: intravenous powder for injection
The most common adverse reactions were nasopharyngitis, headache, arthralgia, nausea, pyrexia, upper respiratory tract infection, fatigue, cough, bronchitis, influenza, back pain, rash, pruritus, sinusitis, oropharyngeal pain, and pain in extremities.
Common (1% to 10%): Rash, pruritus, eczema, erythema, night sweats, acne
Uncommon (0.1% to 1%): Folliculitis
Common (1% to 10%): Nausea, oropharyngeal pain, gastroenteritis, anal abscess, anal fissure, dyspepsia, constipation, abdominal distension, flatulence, hemorrhoids
Frequency not reported: Urinary tract infection
Frequency not reported: Elevations of transaminase, elevations of bilirubin, hepatitis, ALT elevations, AST elevations
Common (1% to 10%): Infusion related reactions (e.g., infusion site reaction, infusion site pain, infusion site irritation)
Very rare (less than 0.01%): Anaphylactic reaction (e.g., dyspnea, bronchospasm, urticaria, flushing, rash, increased blood pressure, increased heart rate)
Common (1% to 10%): Influenza
Uncommon (0.1% to 1%): Bacterial sepsis, septic shock
Frequency not reported: Sepsis, tuberculosis, salmonella sepsis, Listeria meningitis, giardiasis, cytomegaloviral colitis
Very common (10% or more): Arthralgia (12%)
Common (1% to 10%): Back pain, pain in extremities
Very common (10% or more): Headache (12%)
Common (1% to 10%): Paresthesia
Rare (less than 0.1%): Transitional cell carcinoma, carcinoid tumor of the appendix
Frequency not reported: B-cell lymphoma, breast cancer, colon cancer, malignant hepatic neoplasm, malignant lung neoplasm, malignant melanoma, lung cancer of primary neuroendocrine carcinoma, renal cancer, squamous cell carcinoma
Common (1% to 10%): Pyrexia, fatigue
Very common (10% or more): Nasopharyngitis (13%)
Common (1% to 10%): Upper respiratory tract infection, cough, bronchitis, influenza, sinusitis
Very rare (less than 0.01%): Pneumonia
Uncommon (0.1% to 1%): Infusion site reaction (e.g., infusion site pain, infusion site irritation), infusion related reaction, chills, feeling cold
Common (1% to 10%): Hypertension
Medically reviewed by BestRx Medical Team Last updated on 1/1/2020.
Source: Drugs.com Entyvio